A randomized controlled trial comparing myoinositol with metformin versus metformin monotherapy in polycystic ovary syndrome
Authors' conclusion
The addition of myoinositol to metformin exerts additional benefits in improving menstrual cycle regularity, and quality of life in women with PCOS.
Study context
- Population
- Overweight and obese women with PCOS aged 18–35
- Participants
- 26 vs 27
- Comparison
- Metformin plus myoinositol and d-chiro-inositol vs metformin monotherapy
- Myoinositol combinationn = 26
- Metformin monotherapyn = 27reference
Primary result
As reported in the abstract
Menstrual cycle regularity · 6 months
- Menstrual cycle regularity improved in both groups, significantly more with myoinositol-based therapy
- Myoinositol combination vs Metformin monotherapy: P < 0.001
Further findings
Pregnancy rate
- Pregnancy rate was equal in both arms
PCOSQ score
- Significant improvement in PCOSQ score with myoinositol-based therapy
- P < 0.001
Other hormonal and metabolic parameters
- No statistically significant difference between groups
Original publication
A randomized controlled trial comparing myoinositol with metformin versus metformin monotherapy in polycystic ovary syndrome. Clin Endocrinol (Oxf). Published 2 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →